NAFLD Clinical Trial - Probiotic Supplementation IN NAFLD Patients

Status Completed

Clinical Trial Summary

this study aimed to evaluate the effectiveness of Probiotics supplementation (lactobacillus) on NAFLD fibrosis score.

Clinical Trial Description

Non-alcoholic fatty liver disease (NAFLD) is a disease characterized by accumulation of fat (> 5% of the liver tissue), in the absence of alcohol abuse or other chronic liver diseases. NAFLD can cause liver inflammation and progress to non-alcoholic steatohepatitis (NASH), fibrosis, cirrhosis or hepatocellular carcinoma (HCC). The global prevalence of NAFLD in adults is estimated to be approximately 25%.The prevalence of NAFLD increases with increasing body mass index. in 2012 Chalasani et al, reported that 67% of overweight and 94% of obese individuals have NAFLD. There is a consensus regarding increasing worldwide prevalence of NAFLD and its impact on health, especially the progression to liver cirrhosis and hepatocellular carcinoma. Longitudinal studies of NAFLD have reported an increase in all-cause mortality, cardiovascular mortality, and liver-related mortality , NAFLD carries a large economic burden and therefore poor health-related quality of life. Lifestyle changes (diet and exercise) are the major and first suggestions of the guidelines ,as regard pharmaceutical interventions, agents with potential benefit in NASH include thiazolidinediones (TZDs), statins although they are well recognized in the treatment of dyslipidemia, their use as a specific treatment for NAFLD is not well evidenced. There is some data suggest that disruptions in the gut microbiome may play a role in the pathogenesis of NAFLD and progressions to NASH. A probiotic is a live microbial culture or cultured dairy product, which plays an important role in health. Probiotics for the treatment of NAFLD are seemingly a promising treatment option. Relatively easy availability, low cost, and absence of serious side effects make probiotics a lucrative choice. liver biopsy remains the gold standard for NAFLD diagnosis but it is impractical as a diagnostic tool because it is invasive and expensive. NAFLD fibrosis score constructed from routine clinical and laboratory variables can accurately predict the presence or absence of advanced fibrosis in NAFLD. ;

Study Design

Related Conditions & MeSH terms

NAFLD
Non-alcoholic Fatty Liver Disease

Clinical Trial Details

NCT number	NCT06074094
Study type	Interventional
Source	Ain Shams University
Contact
Status	Completed
Phase	Phase 4
Start date	September 12, 2021
Completion date	March 1, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT06101433` - The Effect of Soy Isoflavones on Non-alcoholic Fatty Liver Disease and the Level of FGF-21 and Fetuin A	N/A
Completed	`NCT03289897` - Non-invasive Rapid Assessment of NAFLD Using Magnetic Resonance Imaging With LiverMultiScan	N/A
Active, not recruiting	`NCT05479721` - LITMUS Imaging Study
Completed	`NCT05527938` - Web-based Interventions on Nonalcoholic Fatty Liver Disease (NAFLD) in Obese Children	N/A
Recruiting	`NCT06308757` - Role of the Very Low Calorie Ketogenic Diet (VLCKD) in Patients With Non-Alcoholic Steatohepatitis (NASH) With Fibrosis	N/A
Completed	`NCT02654977` - CLINICAL PROTOCOL to Investigate the Long-term Safety and Efficacy of Metreleptin in Various Forms of Partial Lipodystrophy	Phase 2
Completed	`NCT02927184` - Safety and Tolerability of VK2809 in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease	Phase 2
Completed	`NCT06047847` - Determination of Biological Activity of Enriched Serum Following TOTUM-448 Consumption	N/A
Active, not recruiting	`NCT03534908` - Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: the Correlation Analysis and Risk Prediction Model Study
Recruiting	`NCT06098417` - Biomarkers in the Diagnosis and Prognosis of NAFLD
Recruiting	`NCT04564391` - Whey or Casein - Liver Fat Reduction and Metabolic Improvement by Fast vs. Slow Proteins	N/A
Not yet recruiting	`NCT05984745` - Effect of CoQ10 on the Outcome of MAFLD Patients	Phase 2
Not yet recruiting	`NCT05052515` - The Effects of Natural Extracts Supplementation on NASH Patients	N/A
Recruiting	`NCT02459496` - Diabetes Nutrition Algorithms in Patients With Overt Diabetes Mellitus	N/A
Completed	`NCT01936779` - Understanding the Role of Dietary Fatty Acids on Liver Fat Metabolism in Humans	N/A
Completed	`NCT05844137` - Improving Detection and Evidence-based Care of NAFLD in Latinx and Black Patients With Type 2 Diabetes	N/A
Recruiting	`NCT04664036` - Prevalence, Incidence and Characteristics of NAFLD/NASH in Type 1 Diabetes Mellitus
Recruiting	`NCT04976283` - Effect of Oral Anti-diabetic Medication on Liver Fat in Subjects With Type II Diabetes and Non-alcoholic Fatty Liver	Phase 4
Recruiting	`NCT03587298` - Use of Shear Wave Elastography to Assess Non-alcoholic Fatty Liver Disease (NAFLD)
Completed	`NCT02952170` - Impact of Weight Loss Surgery in Adolescents With NAFLD	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.